Statistics

Total Visits

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study30

Select a period of time:

Number of views in the range

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study21

Views

Views
January 20250
February 20254
March 202515
April 20252
May 20250
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States4
Germany1
Spain1
 

Top cities views

Views
Council Bluffs1
Los Angeles1